FDA Approves Emcitate, First Ever Treatment for MCT8 Deficiency

On September 28, 2026, the U.S. Food and Drug Administration approved Emcitate (tiratricol) tablets for oral suspension, the first therapy ever cleared for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency, a condition also known as Allan-Herndon-Dudley syndrome. The decision ends a long stretch in which families had no FDA-approved medicine for a disorder that shapes nearly every part of daily life, from feeding and speech to heart function.

MCT8 deficiency is a rare genetic disorder that primarily affects males. A faulty gene disrupts the MCT8 transporter, the protein that carries thyroid hormone into the brain, so the brain gets too little hormone while excess builds up in the blood. The FDA lists effects that include inability to walk or sit independently, absent or severely limited speech, intellectual disability, feeding difficulties and chronic stress on the heart and metabolism. The condition is X-linked and caused by pathogenic mutations in the SLC16A2 gene.

Because the transporter itself is broken, a therapy has to reach cells by another route. The FDA said on September 28, 2026 that the active ingredient tiratricol can enter cells on its own without relying on the broken transporter, which allows it to lower elevated blood thyroid hormone levels. Egetis Therapeutics cites a reported median life expectancy of approximately 35 years for people living with the condition.

Approval was granted to Egetis Therapeutics US Inc., part of Egetis Therapeutics AB (publ), which trades on Nasdaq Stockholm under the ticker EGTX and is headquartered in Stockholm, Sweden, with operations in the United States and Europe. Emcitate already holds marketing authorization in the European Union.

Key Facts

The FDA approved Emcitate (tiratricol) on September 28, 2026 for peripheral thyrotoxicosis, described as excess thyroid hormone in the blood causing rapid heart rate, increased blood pressure and metabolic effects. The product is taken once daily as a liquid suspension by mouth or feeding tube, and the tablets contain 350 micrograms. It is not recommended for primary hypothyroidism, is contraindicated in primary hyperthyroidism, and carries a boxed warning stating that it is not for the treatment of obesity or for weight loss.

Evidence came from two clinical studies covering patients from infants to adults: an international, multi-center, randomized, placebo-controlled trial registered as NCT05579327 and a longer-term open-label study. Treated patients had reductions in excess thyroid hormone and improvements in cardiovascular and metabolic symptoms such as systolic blood pressure and heart rate. The wider program also included ReTRIACt, Triac Trial I, Triac Trial II, the Erasmus Medical Center cohort study, the EMC survival study and a U.S. expanded access program.

NovaPharma News reported on September 29, 2026 that the registry record for ReTRIACt lists a Phase 3 design with actual enrollment of 20 participants and a sponsor line that includes Egetis, with a registry start date of July 21, 2023 and completion on September 3, 2025. In that study, males from age 4 who were already on a stable tiratricol dose were randomized either to remain on the drug or to switch to placebo for 30 days, or until serum total T3 rose above the upper limit of normal and rescue treatment was required.

GlobeNewswire reported on September 28, 2026 that Egetis expects Emcitate to be commercially available in the United States eight to ten weeks after approval, and that the company launched Egetis RareLink, a patient support program, in partnership with PANTHERx Rare, covering specialty distribution, education and care coordination, with a support line at 1-844-434-3847. The FDA granted a Rare Pediatric Disease Priority Review Voucher with the approval, and Egetis expects to explore monetization of that voucher, potentially in the fourth quarter of 2026, subject to market conditions.

The most common adverse reactions, reported at or above 5 percent, are diarrhea, vomiting, rash and hyperhidrosis. Patients taking another thyroid medication should talk to a provider first, because the two should not be used together. Emcitate received Orphan Drug, Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations along with Priority Review.

Analysis

What this really means is that the first approval for MCT8 deficiency treats one half of a two-part disease, and regulators drew that boundary deliberately. Tiratricol does not repair the transporter and makes no claim to restore thyroid hormone signalling in the brain; it lowers the excess hormone circulating in the blood. The labeled target is peripheral thyrotoxicosis, the part of the condition that stresses the heart and metabolism, and the improvements documented in the program are framed around systolic blood pressure and heart rate rather than around walking, speech or intellectual disability. That is an honest description of a first step, and it should temper any expectation that one daily dose will change the neurological course of an X-linked disorder.

The bigger picture here is that this is an ultra-rare approval built on a small randomized trial plus a longer open-label study and natural history work from the Erasmus Medical Center cohort and survival studies. The pivotal randomized design enrolled 20 participants, and the core question was whether patients switched to placebo would need rescue treatment once serum total T3 crossed the upper limit of normal. That withdrawal style design suits a condition in which every patient is already on therapy and placebo exposure must be short, 30 days in this case. Small, focused trials of this kind are the realistic path for therapies aimed at populations that may number only in the hundreds worldwide, and the agency's willingness to accept that evidence, backed by priority review and a voucher, tells other sponsors that ultra-rare programs can clear the bar.

Two details in the label also read as regulatory prose about risk. The contraindication in primary hyperthyroidism and the boxed warning that Emcitate is not for the treatment of obesity or for weight loss mark the compound as one that must not drift into weight-loss use, and the instruction that it should not be combined with another thyroid medication places the burden of history taking on prescribers. Together they point to a tightly controlled prescribing channel rather than open-ended use.

Why It Matters

For families, the practical meaning is that a disease with no approved option now has one, and the route of administration fits the population: a once daily liquid suspension that can be given by feeding tube. Marina Zemskova, M.D., Deputy Director of the Division of General Endocrinology in the FDA's Center for Drug Evaluation and Research, said that until now, patients living with MCT8 deficiency and their families had no FDA-approved treatment option. Hylton V. Joffe, M.D., MMSc, Director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology, pointed to the transporter-independent mechanism as the reason tiratricol can lower elevated blood thyroid hormone levels.

Timing of diagnosis is the other half of the story. Andrew J. Bauer, M.D., a pediatric endocrinologist and Principal Investigator in ReTRIACt and Triac Trial II, said early diagnosis is critical. With a reported median life expectancy of approximately 35 years and chronic cardiac and metabolic stress, each year of untreated peripheral thyrotoxicosis adds strain. A therapy that reduces systolic blood pressure and heart rate addresses the part of the disease most likely to shorten lives.

Nicklas Westerholm, chief executive officer of Egetis, called the approval a turning point. Whether it functions as one depends less on the decision itself than on how quickly infants and young boys are tested for SLC16A2 mutations and how early treatment starts, given that the pivotal evidence came largely from patients who were already on stable tiratricol therapy before randomization.

Next Up

Egetis will host an analyst and investor call on Tuesday, September 29, 2026 at 8:00 am CEST, which is 2:00 am EDT. U.S. supply is expected eight to ten weeks after approval, with PANTHERx Rare handling specialty distribution through the RareLink program. Egetis also intends to explore monetization of its Rare Pediatric Disease Priority Review Voucher, potentially in the fourth quarter of 2026, subject to market conditions.

What remains unanswered will also be what is watched. NovaPharma News noted on September 29, 2026 that neither the FDA notice nor the company release prints a numeric drop in T3, a blood pressure delta or a heart rate delta, and Egetis has not published a U.S. list price. Those gaps will shape how payers and clinicians judge the drug in its first year, along with real-world data on how long cardiovascular and metabolic benefits hold in patients treated from infancy rather than from age 4 and older.